RNA interference targets the placenta
Nature Biotechnology
November 20, 2018
RNA interference, an emerging therapeutic strategy for silencing disease-causing genes, reduces expression in the mouse and baboon placenta of a gene responsible for preeclampsia, reports a study published online this week in Nature Biotechnology. Further animal studies of efficacy and safety are needed before this approach could be considered for clinical trials in women with preeclampsia, a disorder of high blood pressure that affects 5-10 percent of pregnancies.
Preeclampsia symptoms arise from abnormally high circulating levels of the protein sFLT1, which is produced in the placenta and secreted into the blood. sFLT1 is considered a promising therapeutic target, and several approaches to lower its activity have been tested.
Anastasia Khvorova and colleagues block sFlt1 synthesis in the placenta using small interfering RNA (siRNA) delivered intravenously or subcutaneously. The treatment reduces circulating levels of sFlt 1 in pregnant mice and in a baboon model of preeclampsia. In contrast to previous work, the approach is demonstrated with only a single injection and suppresses sFlt1 right where it is produced, in the placenta. The development of siRNA therapies has been largely focused on the liver, and the ability to target the placenta may open new therapeutic avenues.
doi:10.1038/nbt.4297
Research highlights
-
Jun 29
Environment: 1.81 billion people at risk of 1-in-100 year floodNature Communications
-
Jun 29
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
Jun 28
Astronomy: Hydrogen- and helium-rich exoplanets may provide habitable conditions for billions of yearsNature Astronomy
-
Jun 28
Climate change: Decline in tropical cyclones during the twentieth centuryNature Climate Change
-
Jun 24
Environment: Assessing the impacts of US school lunches on climate, land and waterCommunications Earth & Environment
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports